PRESS RELEASE published on 10/16/2025 at 19:58, 1 month 19 days ago RAPPORT FINANCIER SEMESTRIEL 2025
BRIEF published on 10/15/2025 at 19:05, 1 month 20 days ago OSE Immunotherapeutics Reports 2025 First Half Financial Results Revenue Decline OSE Immunotherapeutics Cash Runway R&D Expenses 2025 Financial Results
BRIEF published on 10/15/2025 at 19:05, 1 month 20 days ago OSE Immunotherapeutics publie ses résultats financiers du premier semestre 2025 Baisse Des Revenus OSE Immunotherapeutics Dépenses De R&D Piste De Trésorerie Résultats Financiers 2025
PRESS RELEASE published on 10/15/2025 at 19:00, 1 month 20 days ago OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025 OSE Immunotherapeutics publie ses résultats financiers du 1er semestre 2025, montrant une perte nette de 15,1 millions d'euros. Les activités sont estimées financées jusqu'au 4ème trimestre 2026 Résultats Financiers Biotechnologie Perte Nette OSE Immunotherapeutics Horizon De Trésorerie
PRESS RELEASE published on 10/15/2025 at 19:00, 1 month 20 days ago OSE Immunotherapeutics Reports First Half 2025 Financial Results OSE Immunotherapeutics reports first half 2025 financial results with operating loss of 15.8 million euros and net loss of 15.1 million euros. Research and development expenses increased 6.7% Financial Results Net Loss Operating Loss OSE Immunotherapeutics Research And Development Expenses
BRIEF published on 10/09/2025 at 16:02, 1 month 26 days ago OSE Immunotherapeutics : Fin d'une action de concert entre actionnaires Actionnaires Franchissement De Seuil Capital Et Droits De Vote OSE Immunotherapeutics Pacte Résilié
BRIEF published on 10/09/2025 at 16:02, 1 month 26 days ago OSE Immunotherapeutics: End of a concerted action between shareholders Shareholders Threshold Crossing OSE Immunotherapeutics Capital And Voting Rights Terminated Agreement
PRESS RELEASE published on 10/09/2025 at 15:57, 1 month 26 days ago Franchissement de seuils Fin de convention et action de concert chez OSE Immunotherapeutics suite à franchissement de seuils de M. Emile Loria, Mme Dominique Costantini, M. Alexis Peyroles, MS Medical Synergy SA et Aperana Consulting SARL OSE Immunotherapeutics Franchissement Seuils Fin Convention Action Concert Emile Loria
BRIEF published on 09/30/2025 at 19:35, 2 months 4 days ago OSE Immunotherapeutics: Reorganization of the Board of Directors Board Of Directors Biotechnology Immunotherapy OSE Immunotherapeutics Markus Cappel
BRIEF published on 09/30/2025 at 19:35, 2 months 4 days ago OSE Immunotherapeutics : Réorganisation du Conseil d'administration Biotechnologie Conseil D'administration Immunothérapie OSE Immunotherapeutics Markus Cappel
Published on 12/05/2025 at 02:35, 4 hours 6 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 5 hours 41 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 36 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 41 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 03:30, 3 hours 10 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 50 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 15 minutes ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 26 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 11 hours 30 minutes ago SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance
Published on 12/04/2025 at 18:14, 12 hours 26 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 12 hours 41 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 12 hours 41 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 56 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 12 hours 56 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
